Ayahuasca and Depression: Evidence, Medication, Suicide Risk and Screening

Ayahuasca and depression have received unusual scientific attention compared with many other retreat claims. A small randomized trial found rapid symptom improvement in people with treatment-resistant depression. That result is promising, but it does not establish ayahuasca as an approved treatment, prove long-term benefit or make a commercial retreat equivalent to psychiatric care.

Depression ranges from persistent low mood and loss of interest to severe impairment, psychosis or suicidal risk. It may occur as major depression, persistent depressive disorder, perinatal depression or part of bipolar disorder. These distinctions change medication, risk and the support someone may need. A retreat intake form cannot replace diagnosis or individualized treatment.

What the randomized ayahuasca trial found

The best-known controlled trial enrolled 29 people with treatment-resistant depression and randomly assigned a single dose of ayahuasca or placebo. Depression scores were lower in the ayahuasca group at one, two and seven days. At day seven, 64% met the study’s response criterion compared with 27% in the placebo group.

Remission was reported in 36% of the ayahuasca group and 7% of the placebo group at day seven, but that difference only showed a statistical trend and did not cross the conventional threshold for significance. This distinction matters: promising numbers should not be promoted as a guaranteed remission rate.

The trial was carefully monitored and used psychiatric assessments and defined eligibility. It did not test repeated ceremonies, unknown-strength brews, long-distance travel or a routine commercial retreat. Twenty-nine participants are too few to identify uncommon harms or determine who will benefit.

Follow-up in the primary report ended at seven days. Depression is often recurrent, so a brief change does not establish durable recovery, relapse prevention or the safety of abandoning existing treatment.

Why placebo, expectation and setting matter

Psychedelic trials are difficult to blind because the active effects are obvious to many participants. Expectations, attention, ritual, support and relief at receiving a hoped-for intervention may influence symptom scores. This does not mean improvement is unreal; it means researchers must separate the contribution of the drug from the surrounding care.

A placebo-controlled naturalistic study of 30 experienced retreat participants found that depression, anxiety and stress symptoms improved after ceremonies in both the ayahuasca and placebo groups, independent of treatment assignment. That study was also small, but it demonstrates that set, setting and expectation can produce measurable change.

A commercial center should not present the 29-person clinical trial as proof of its own brew, staff, protocol or outcomes. Read our broader overview of ayahuasca safety, risks and contraindications.

What newer reviews add

A 2026 review of 18 prospective ayahuasca studies found preliminary long-term changes in wellbeing, depression and other mental-health outcomes. Most studies enrolled volunteers already attending retreats, and many had small samples, unstandardized doses, no control group and nonrandomized designs. Subsets of participants also experienced persisting psychiatric complications.

A living meta-analysis that combined different serotonergic psychedelics rated evidence for major depression as very low certainty. An umbrella review found that ayahuasca had far fewer meta-analyses than psilocybin for depression. Results from psilocybin, ketamine, esketamine or DMT cannot simply be transferred to ceremonial ayahuasca.

A 2026 scoping review of registered ayahuasca and DMT trials described a field dominated by early-stage studies, conservative eligibility and substantial medical and psychiatric exclusions. That is very different from accepting any paying guest.

Depression is not one screening checkbox

Responsible screening should ask about the diagnosis, duration, severity and current function. Relevant information includes:

• low mood, loss of interest, hopelessness, guilt and concentration difficulty;
• sleep, appetite, energy, work, self-care and social withdrawal;
• thoughts of death, self-harm, suicidal thoughts, plans or past attempts;
• psychosis, severe agitation, catatonia or inability to eat or drink;
• past periods of unusually high energy, little need for sleep or risky behavior;
• psychiatric hospitalization, emergency care and recent rapid deterioration;
• current and previous medication, recent changes and withdrawal reactions;
• alcohol, cannabis, stimulants, opioids and other substance use; and
• pregnancy, medical conditions and physical causes that may affect mood.

The National Institute of Mental Health notes that medical conditions and medicines can resemble or contribute to depression. A clinical assessment can review thyroid, neurological, sleep, pain and other factors that a retreat cannot diagnose.

Suicidal risk needs a direct plan

Asking directly about suicide does not create the idea. Screening should address current thoughts, intent, a plan, access to lethal means, recent attempts, protective factors and the person’s ability to stay safe. Vague questions such as “Are you emotionally stable?” are not enough.

A person with current intent, a plan, inability to maintain safety or rapidly worsening severe depression needs urgent assessment through local emergency or crisis services. They should not travel to a remote retreat as a substitute for care. A ceremony is not a controlled suicide intervention, and retreat staff cannot promise that an altered state will remove the danger.

When risk is not acute but a history exists, the treating clinician should guide whether travel is appropriate. A written safety plan, trusted contact, secure medication, scheduled follow-up and clear emergency pathway are minimum considerations. If risk increases at any point, further ceremonies should stop.

Do not stop antidepressants for a booking

Ayahuasca commonly combines DMT with beta-carbolines that inhibit monoamine oxidase A. Antidepressants and other psychiatric medicines raise interaction, withdrawal and relapse questions that depend on the exact medicine, dose, formulation, duration and personal history.

Abrupt discontinuation can produce physical and psychological symptoms or allow depression to return. Some people take additional medicines for anxiety, sleep, psychosis, bipolar disorder, seizures or pain. An online washout table cannot assess that combination.

A retreat should not prescribe a taper or guarantee a safe date. Give the prescriber the proposed travel dates, number of ceremonies and retreat policy. Give the retreat the accurate medication list and clinical recommendation. Our guide to ayahuasca and antidepressant interactions explains the issue in detail.

Rule out bipolar depression and psychotic depression

A depressive episode can occur within bipolar disorder. Past mania or hypomania may have felt productive, spiritual or simply unlike depression, so it is often missed. Ask about periods of very little sleep with high energy, pressured speech, racing thoughts, grandiosity, unusual confidence, impulsive spending or other risky behavior.

Psychedelics, sleep disruption and medication changes may contribute to mania or psychosis in susceptible people. A family history of bipolar disorder or psychosis is also relevant. Depression with delusions, hallucinations or severe disorganization requires clinical assessment.

See our dedicated guide to ayahuasca, bipolar disorder, mania and psychosis.

Build continuity of care before travel

Discuss the retreat with the clinician who knows the depression history. Share the destination, dates, travel time, medication policy, ceremony schedule and actual medical resources. The clinician may advise postponing or not participating. That is a safety decision, not a treatment failure.

A practical plan should identify:

• who will monitor medication adherence and symptom change;
• a trusted contact who knows the itinerary and baseline behavior;
• personal warning signs of worsening depression or activation;
• what triggers stopping additional ceremonies;
• how urgent psychiatric or medical transfer occurs;
• where the person will stay after the final ceremony; and
• a confirmed clinical appointment after returning home.

Insurance may exclude pre-existing conditions or substance-related events. Check the policy wording using our travel insurance guide.

Travel can temporarily reduce stability

Long flights, time-zone changes, unfamiliar food, heat, isolation and disrupted sleep can worsen mood before the ceremony. Remote lodges may be far from the person’s clinician and support network. A participant who already struggles with eating, hydration, self-care or mobility may need more support than a retreat can provide.

Ask whether someone can skip a ceremony without pressure, how staff respond to withdrawal or persistent crying, and how quickly transport reaches ordinary medical care. Payment already made should not determine whether travel continues.

After the ceremony, improvement is not the only possibility

Some people report relief, hope or increased connection. Others may feel exhausted, ashamed, emotionally raw, unable to sleep or disappointed that symptoms remain. A meaningful experience and ongoing depression can coexist.

Staff should not promise that distress will resolve if the person simply trusts the process. Severe withdrawal, hopelessness, agitation, psychosis, inability to eat or drink, or suicidal thinking requires assessment. Do not give another psychoactive substance to counteract symptoms.

Physical problems can also worsen mental state. Persistent vomiting, dehydration, fever, chest pain, seizure or reduced consciousness needs medical care; see our guide to purging and emergency warning signs.

Follow-up should measure function and safety

Arrange follow-up before travel rather than waiting to see how the ceremony goes. Review mood, interest, sleep, appetite, energy, concentration, self-care, work, relationships, substance use and suicidal thinking. Record both improvement and deterioration.

Continue established treatment according to the clinician’s plan. Avoid additional psychedelics, heavy alcohol use and major irreversible decisions while mood is unsettled. NIMH advises delaying important life decisions during depression and discussing them with trusted people.

Integration may support reflection, but it is not a replacement for licensed depression treatment. A coach or facilitator should not diagnose remission, alter medication or discourage contact with the person’s clinical team.

Watch for activation, not only low mood

A sudden lift in mood is not always recovery. Concern rises when it includes very little need for sleep, rapidly increasing energy, pressured speech, racing thoughts, grandiosity, impulsivity or loss of reality testing. These changes may indicate mania or another developing crisis.

Stop further ceremonies and obtain prompt assessment if activation escalates. Do not celebrate dangerous behavior as a spiritual breakthrough.

Urgent warning signs

Seek urgent help through local emergency or crisis services when a person has suicidal intent or a plan, cannot commit to immediate safety, attempts self-harm, becomes violent, loses contact with reality, wanders, stops eating or drinking, or cannot perform basic self-care.

Do not leave the person alone. Reduce access to immediate hazards, communicate calmly and share the exposure timeline, medicines, other substances and psychiatric history with clinicians. A remote retreat should activate its transfer plan rather than trying to manage a severe crisis indefinitely on site.

Retreat claims that should make you pause

Be cautious when a provider:

• advertises ayahuasca as a proven cure for depression;
• quotes the 29-person trial without explaining its size and seven-day follow-up;
• never asks directly about suicide, mania, psychosis or hospitalization;
• encourages concealment or abrupt medication discontinuation;
• accepts someone in an active psychiatric crisis;
• has no sober overnight staff or emergency transfer plan;
• discourages evidence-based treatment or follow-up; or
• frames worsening depression as proof that healing is working.

Compare providers using our guide to choosing a safer ayahuasca retreat in Peru.

Frequently asked questions

Is ayahuasca approved for depression?

No. Ayahuasca is not an approved depression treatment. Research remains preliminary and is not equivalent to routine clinical use.

What did the randomized trial prove?

It found short-term symptom improvement in a small, carefully monitored sample. It did not prove long-term effectiveness, safety for all patients or the effectiveness of commercial retreats.

Can ayahuasca cure treatment-resistant depression?

No cure can be promised. One small trial found a higher response rate at seven days, while remission only showed a statistical trend. Replication and longer follow-up are needed.

Should antidepressants be stopped before a retreat?

Not without the prescriber. Interaction, discontinuation and relapse risks are individualized, and a retreat should not direct a medical taper.

Can someone with suicidal thoughts attend?

Current intent, a plan or inability to stay safe requires urgent clinical care, not a retreat. Other histories still need individualized assessment and a documented safety plan.

Is feeling energized after a ceremony always improvement?

No. Reduced need for sleep, racing thoughts, grandiosity and unsafe behavior may signal mania or another crisis and require assessment.

Hope needs honest limits

Ayahuasca research in depression is more developed than many retreat claims, but it remains small and early. A positive seven-day trial cannot answer long-term questions or replace psychotherapy, medication, crisis care and individualized medical judgment.

Review Ayaterra’s ayahuasca retreats near Iquitos and contact the team for current screening requirements. Disclose depression, suicidal history, bipolar symptoms, medication and previous severe reactions before booking.

Research and health sources

• Randomized placebo-controlled trial of ayahuasca in 29 people with treatment-resistant depression
• Placebo-controlled study of ayahuasca, set and setting at group retreats
• 2026 systematic review of prospective long-term ayahuasca studies
• 2026 scoping review of registered ayahuasca and DMT trials
• Living systematic review and meta-analysis of psychedelics for mental disorders
• Global Ayahuasca Survey report on adverse effects
• Systematic review of drug interactions involving classic psychedelics
• National Institute of Mental Health: depression overview and treatment

Medical disclaimer: This article provides general education and does not diagnose depression, recommend ayahuasca or determine personal retreat safety. Do not start, stop or change psychiatric medication without qualified clinical guidance. Current suicidal intent, inability to stay safe, severe psychosis or life-threatening symptoms require urgent local emergency or crisis care.